A Case of Hypercalcemia from PTHrP-Producing Fibromyxoid Sarcoma Responsive to Glucocorticoid Therapy.
A Case of Hypercalcemia from PTHrP-Producing Fibromyxoid Sarcoma Responsive to Glucocorticoid Therapy.
复制标题
DOI：
10.1007/s00223-023-01099-8
复制
发表时间：
2023-08
影响因子：
4.2
通讯作者：
中科院分区：
文献类型：
--
作者：
甲状旁腺相关蛋白（PTHrP）介导的恶性肿瘤高钙血症的治疗包括治疗恶性肿瘤、静脉输液和抗吸收治疗，如唑来膦酸或狄诺塞单抗。PTHrP介导的高钙血症在良性疾病如系统性红斑狼疮（SLE）和结节病中已有报道，并且似乎对糖皮质激素有反应。我们报告一例PTHrP诱导的高钙血症由于恶性低级别纤维粘液样肉瘤，糖皮质激素治疗反应。这是第一次报告糖皮质激素控制PTHrP介导的恶性高钙血症。手术病理的免疫组织化学定位于肿瘤内的血管内皮细胞的PTHrP染色。糖皮质激素治疗PTHrP介导的恶性肿瘤高钙血症的作用机制有待进一步研究。在线版本包含补充材料，可通过10.1007/s 00223 -023-01099-8获得。
The treatment of parathyroid hormone-related protein (PTHrP)-mediated hypercalcemia of malignancy includes treating the malignancy, intravenous fluids, and anti-resorptive therapies such as zoledronic acid or denosumab. PTHrP-mediated hypercalcemia has been reported in benign conditions such as systemic lupus erythematous (SLE) and sarcoidosis and appears to be responsive to glucocorticoids. We report a case of PTHrP-induced hypercalcemia due to a malignancy—low grade fibromyxoid sarcoma—that responded to glucocorticoid treatment. This is the first report of glucocorticoids controlling PTHrP-mediated hypercalcemia of malignancy. Immunohistochemistry of the surgical pathology localized PTHrP staining to the vascular endothelial cells within the tumor. Further studies are needed to elucidate the mechanism of glucocorticoid action in the treatment of PTHrP-mediated hypercalcemia of malignancy. The online version contains supplementary material available at 10.1007/s00223-023-01099-8.
影响因子：
--
作者：
Kim DW;Miller A;Li A;Hardy N;Silver KD
通讯作者：
Silver KD